OKYO.L Share News (OKYO)

IN BRIEF: Okyo Pharma to move shares to New York with London delisting

Okyo Pharma Ltd - Guernsey-based ophthalmology-focused bio-pharmaceutical company, currently developing OK-101 to treat dry eye disease - New shares will be listed on Nasdaq in New York from Monday, following a share consolidation and the termination of its American depository share programme. Okyo has been listed on Nasdaq via the ADS programme since May last year. Okyo shares will be de-listed from the London Stock Exchange on Monday. De-listing had been planned for a week ago but was postponed. Each new Okyo share will represent 65 old shares and be equal to one old ADS.

IN BRIEF: Okyo Pharma delays delisting from London trading to May 22

Okyo Pharma Ltd - UK-based ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease - Delays delisting from London Stock Exchange until May 22. Was previously due on Friday. Says this will have no effect on its American depositary shares trading on Nasdaq in New York. In April, it said the decision to cancel its listing was due to the number of shares trading being "negligible and does not justify the associated costs".

TRADING UPDATES: Knights Group buys St James Law and Baines Wilson

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days

TRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facility

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

SMALL-CAP WINNERS & LOSERS: African Pioneer secures project clearance

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

Okyo Pharma applies to delist from London Stock Exchange due to costs

(Alliance News) - Okyo Pharma Ltd on Tuesday said it has applied to the UK Financial Conduct Authority and the London Stock Exchange PLC to delist its shares from London's Main Market and the standard segments of the FCA's official list.

OKYO Pharma to delist from LSE

(Sharecast News) - Ophthalmology-focused bio-pharmaceutical company OKYO Pharma said on Tuesday that it has applied to delist from the London Stock Exchange.

TRADING UPDATES: Inspirit Energy reports progress on Inspirit Charger

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Inspirit Energy reports progress on Inspirit Charger

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Okyo says OK-101 clears US customs, to be used in phase 2 trial

(Alliance News) - Okyo Pharma Ltd on Tuesday said its good manufacturing practice-packaged OK-101 drug has cleared customs in the US.

Okyo Pharma interim loss multiplies, expects to initiate phase 2 trial

(Alliance News) - Okyo Pharma Ltd's half-year loss widened dramatically, while it also said on Friday it expects to initiate phase 2 of a clinical trial of its dry eye disease treatment OK-101 in early 2023.

IN BRIEF: Okyo Pharma wins US FDA clearance for dry eye treatment

Okyo Pharma Ltd - London-based ophthalmology-focused bio-pharmaceutical company - Receives clearance of its investigational new drug application from the US Food & Drug Administration to begin a phase two first-in-human clinical study of OK-101 for the treatment dry eye disease.

TRADING UPDATES: 7digital loan pact; Okyo Pharma files with SEC

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

TRADING UPDATES: Okyo Pharma files IND; Reabold Co-CEOs buy shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: